We identified an overall of 6 placebo-controlled randomized cardiovascular outcome trials (EMPA-REG OUTCOME2, CANVAS Program3, DECLARE-TIMI 584, CREDENCE5, VERTIS CV6, and SCORED7) of three selective SGLT2 inhibitors (empagliflozin2, dapagliflozin4, and ertugliflozin6) and two SGLT2 inhibitors with clinically relevant SGLT1-inhibitory property (canagliflozin3,5 and sotagliflozin7), including a total of 57,553 patients with type 2 diabetes mellitus and high cardiovascular risk (Table 1). This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.